 Connection
Thomas Flaig to ErbB Receptors
This is a "connection" page, showing publications Thomas Flaig has written about ErbB Receptors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.777 |
|
|
|
-
Yang X, Flaig TW. Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol. 2010 May-Jun; 36(3):273-82.
Score: 0.279
-
Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37.
Score: 0.256
-
Bourlon MT, Flaig TW. The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma. Curr Drug Targets. 2016; 17(2):196-205.
Score: 0.103
-
Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glod? LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res. 2013 Jan 01; 19(1):148-57.
Score: 0.083
-
Cho SK, Su LJ, Mao C, Wolenski CD, Flaig TW, Park W. Multifunctional nanoclusters of NaYF4:Yb3+,Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Mater Sci Eng C Mater Biol Appl. 2019 Apr; 97:784-792.
Score: 0.032
-
Cho SK, Emoto K, Su LJ, Yang X, Flaig TW, Park W. Functionalized gold nanorods for thermal ablation treatment of bladder cancer. J Biomed Nanotechnol. 2014 Jul; 10(7):1267-76.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|